<SEC-DOCUMENT>0001102598-24-000178.txt : 20241107
<SEC-HEADER>0001102598-24-000178.hdr.sgml : 20241107
<ACCEPTANCE-DATETIME>20241107144936
ACCESSION NUMBER:		0001102598-24-000178
CONFORMED SUBMISSION TYPE:	SC 13G/A
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20241107
DATE AS OF CHANGE:		20241107

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Sanofi
		CENTRAL INDEX KEY:			0001121404
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				133529324
		STATE OF INCORPORATION:			I0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SC 13G/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-60069
		FILM NUMBER:		241434811

	BUSINESS ADDRESS:	
		STREET 1:		46 AVENUE DE LA GRANDE ARMEE
		CITY:			PARIS
		STATE:			I0
		ZIP:			75017
		BUSINESS PHONE:		33153774400

	MAIL ADDRESS:	
		STREET 1:		46 AVENUE DE LA GRANDE ARMEE
		CITY:			PARIS
		STATE:			I0
		ZIP:			75017

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SANOFI-AVENTIS
		DATE OF NAME CHANGE:	20040826

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SANOFI SYNTHELABO SA
		DATE OF NAME CHANGE:	20010104

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Amundi
		CENTRAL INDEX KEY:			0001330387
		ORGANIZATION NAME:           	
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			I0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SC 13G/A

	BUSINESS ADDRESS:	
		STREET 1:		91-93 BOULEVARD PASTEUR
		CITY:			PARIS
		STATE:			I0
		ZIP:			75015
		BUSINESS PHONE:		33 1 43 23 30 30

	MAIL ADDRESS:	
		STREET 1:		91-93 BOULEVARD PASTEUR
		CITY:			PARIS
		STATE:			I0
		ZIP:			75015

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Amundi Group
		DATE OF NAME CHANGE:	20100122

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Credit Agricole Asset Management Group
		DATE OF NAME CHANGE:	20060123

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Segespar
		DATE OF NAME CHANGE:	20050616
</SEC-HEADER>
<DOCUMENT>
<TYPE>SC 13G/A
<SEQUENCE>1
<FILENAME>sanofi.htm
<DESCRIPTION>SCHEDULE 13GA
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Amundi
         Document created using Broadridge PROfile 24.9.1.5252
         Copyright 1995 - 2024 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div style="text-align: center;">SECURITIES AND EXCHANGE COMMISSION</div>
    <div style="text-align: center;">WASHINGTON, D.C. 20549</div>
    <div><br>
    </div>
    <div style="text-align: center;">SCHEDULE 13G*</div>
    <div style="text-align: center;">(Rule 13d-102)</div>
    <div><br>
    </div>
    <div style="text-align: center;">INFORMATION TO BE INCLUDED</div>
    <div style="text-align: center;">IN STATEMENTS FILED PURSUANT</div>
    <div style="text-align: center;">TO RULES 13d-1(b), (c), AND</div>
    <div style="text-align: center;">(d) AND AMENDMENTS THERETO</div>
    <div style="text-align: center;">FILED PURSUANT TO RULE 13d-2</div>
    <div style="text-align: center;">(AMENDMENT NO. 5 )*</div>
    <div><br>
    </div>
    <div>Name of issuer:&#160; Sanofi</div>
    <div><br>
    </div>
    <div>Title of Class of Securities:&#160; Common Stock and American Depositary Receipts</div>
    <div><br>
    </div>
    <div>CUSIP Number:&#160; Not Applicable** and 80105N105</div>
    <div><br>
    </div>
    <div>Date of Event Which Requires Filing of this Statement: September 30, 2024</div>
    <div><br>
    </div>
    <div>Check the appropriate box to designate the rule pursuant to which this Schedule is filed:</div>
    <div><br>
    </div>
    <div><font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9746;</font>&#8195;Rule 13d-1(b)</div>
    <div><br>
    </div>
    <div><font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</font>&#8195;Rule 13d-1(c)</div>
    <div><br>
    </div>
    <div><font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</font>&#8195;Rule 13d-1(d)</div>
    <div><br>
    </div>
    <div>*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities,
      and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.</div>
    <div><br>
    </div>
    <div>The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
      1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).</div>
    <div><br>
    </div>
    <div>** The CUSIP number is not applicable. The Reporting Persons hold common stock with ISIN FR0000120578.</div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div>1.&#160; NAME OF REPORTING PERSONS</div>
    <div>I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)</div>
    <div><br>
    </div>
    <div>Amundi</div>
    <div><br>
    </div>
    <div>2.&#160; CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP</div>
    <div><br>
    </div>
    <div>(a)<font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</font></div>
    <div>(b)<font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</font></div>
    <div><br>
    </div>
    <div>3.&#160; SEC USE ONLY</div>
    <div><br>
    </div>
    <div>4.&#160; CITIZENSHIP OR PLACE OF ORGANIZATION</div>
    <div><br>
    </div>
    <div>Republic of France</div>
    <div><br>
    </div>
    <div>(For questions 5-8, report the number of shares beneficially owned by each reporting person with:)</div>
    <div><br>
    </div>
    <div>5.&#160; SOLE VOTING POWER</div>
    <div><br>
    </div>
    <div>0</div>
    <div><br>
    </div>
    <div>6.&#160; SHARED VOTING POWER</div>
    <div><br>
    </div>
    <div>29,091,483</div>
    <div><br>
    </div>
    <div>7.&#160; SOLE DISPOSITIVE POWER</div>
    <div><br>
    </div>
    <div>0</div>
    <div><br>
    </div>
    <div>8.&#160; SHARED DISPOSITIVE POWER</div>
    <div><br>
    </div>
    <div>64,569,630</div>
    <div><br>
    </div>
    <div>9.&#160; AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON***</div>
    <div><br>
    </div>
    <div>64,569,630</div>
    <div><br>
    </div>
    <div>10.&#160; CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)</div>
    <div><br>
    </div>
    <div><font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</font> Not Applicable</div>
    <div><br>
    </div>
    <div>11.&#160; PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)</div>
    <div><br>
    </div>
    <div>5.1%</div>
    <div><br>
    </div>
    <div>12.&#160; TYPE OF REPORTING PERSON</div>
    <div><br>
    </div>
    <div>HC<br>
      <br>
    </div>
    <div>*** Of this number, Amundi does not have the voting rights on 24,885,338 shares which are held through a &#171; FCPE &#187; (&#171; Fonds Commun de Placement d&#8217;Entreprise &#187;,
      an investment vehicle established under French law), solely dedicated to Sanofi group&#8217;s employees shareholding. Employees of Sanofi are granted the right to participate in stock purchase plans in which the shares acquired are exclusively held in this
      FCPE, created at the request of Sanofi. The voting rights associated to these shares are exercised by the supervisory Board of the FCPE, where representatives of the employees have the majority (if any the remaining seats of the supervisory board are
      designated by Sanofi), and not by Amundi.</div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div>1.&#160; NAME OF REPORTING PERSONS</div>
    <div>I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)</div>
    <div><br>
    </div>
    <div>Amundi Asset Management</div>
    <div><br>
    </div>
    <div>2.&#160; CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP</div>
    <div><br>
    </div>
    <div>(a)<font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</font></div>
    <div>(b)<font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</font></div>
    <div><br>
    </div>
    <div>3.&#160; SEC USE ONLY</div>
    <div><br>
    </div>
    <div>4.&#160; CITIZENSHIP OR PLACE OF ORGANIZATION</div>
    <div><br>
    </div>
    <div>Republic of France</div>
    <div><br>
    </div>
    <div>(For questions 5-8, report the number of shares beneficially owned by each reporting person with:)</div>
    <div><br>
    </div>
    <div>5.&#160; SOLE VOTING POWER</div>
    <div><br>
    </div>
    <div>0</div>
    <div><br>
    </div>
    <div>6.&#160; SHARED VOTING POWER</div>
    <div><br>
    </div>
    <div>29,091,483</div>
    <div><br>
    </div>
    <div>7.&#160; SOLE DISPOSITIVE POWER</div>
    <div><br>
    </div>
    <div>0</div>
    <div><br>
    </div>
    <div>8.&#160; SHARED DISPOSITIVE POWER</div>
    <div><br>
    </div>
    <div>64,569,630</div>
    <div><br>
    </div>
    <div>9.&#160; AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON***</div>
    <div><br>
    </div>
    <div>64,569,630</div>
    <div><br>
    </div>
    <div>10.&#160; CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)</div>
    <div><br>
    </div>
    <div><font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</font> Not Applicable</div>
    <div><br>
    </div>
    <div>11.&#160; PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)</div>
    <div><br>
    </div>
    <div>5.1%</div>
    <div><br>
    </div>
    <div>12.&#160; TYPE OF REPORTING PERSON</div>
    <div><br>
    </div>
    <div>FI</div>
    <div> <br>
    </div>
    <div>*** Of this number, Amundi does not have the voting rights on 24,885,338 shares which are held through a &#171; FCPE &#187; (&#171; Fonds Commun de Placement d&#8217;Entreprise &#187;,
      an investment vehicle established under French law), solely dedicated to Sanofi group&#8217;s employees shareholding. Employees of Sanofi are granted the right to participate in stock purchase plans in which the shares acquired are exclusively held in this
      FCPE, created at the request of Sanofi. The voting rights associated to these shares are exercised by the supervisory Board of the FCPE, where representatives of the employees have the majority (if any the remaining seats of the supervisory board are
      designated by Sanofi), and not by Amundi.</div>
    <div><br>
    </div>
    <div>Item 1(a) - Name of Issuer:</div>
    <div><br>
    </div>
    <div>Sanofi</div>
    <div><br>
    </div>
    <div>Item 1(b) - Address of Issuer's Principal Executive Offices:</div>
    <div><br>
    </div>
    <div>46 AVENUE DE LA GRANDE ARMEE, PARIS, France, 75017</div>
    <div><br>
    </div>
    <div>Item 2(a) - Name of Person Filing:</div>
    <div><br>
    </div>
    <div>Amundi</div>
    <div>Amundi Asset Management</div>
    <div><br>
    </div>
    <div>Item 2(b) &#8211; Address of Principal Business Office or, if none, Residence:</div>
    <div><br>
    </div>
    <div>Amundi</div>
    <div>91-93 boulevard Pasteur</div>
    <div>75015 Paris, France</div>
    <div><br>
    </div>
    <div>Amundi Asset Management</div>
    <div>90 boulevard Pasteur</div>
    <div>75015 Paris, France</div>
    <div><br>
    </div>
    <div>Item 2(c) &#8211; Citizenship:</div>
    <div><br>
    </div>
    <div>Both Amundi and Amundi Asset Management are organized under the laws of the Republic of France.</div>
    <div><br>
    </div>
    <div>Item 2(d) - Title of Class of Securities:</div>
    <div><br>
    </div>
    <div>Common Stock and American Depositary Receipts</div>
    <div><br>
    </div>
    <div>Item 2(e) - CUSIP Number</div>
    <div><br>
    </div>
    <div>The Reporting Persons hold common stock with ISIN FR0000120578. The Reporting Persons hold American Depositary Receipts with CUSIP 80105N105.</div>
    <div><br>
    </div>
    <div>Item 3 - If This Statement Is Filed Pursuant to Sections 240.13d-1(b) or 240.13d-2(b) or (c), Check Whether the Person Filing Is a(n):</div>
    <div><br>
    </div>
    <div>(a) <font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</font> Broker or dealer registered under Section 15 of the Act (15 U.S.C.
      78o)&#894;</div>
    <div>(b) <font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</font> Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c)&#894;</div>
    <div>(c) <font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</font> Insurance company as defined in Section 3(a)(19) of the Act (15
      U.S.C. 78c)&#894;</div>
    <div>(d) <font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</font> Investment company registered under Section 8 of the Investment
      Company Act of 1940 (15 U.S.C. 80a-8)&#894;</div>
    <div>(e) <font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</font> Investment adviser in accordance with Section 240.13d-1(b)(1)(ii)(E)&#894;</div>
    <div>(f) <font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</font> Employee benefit plan or endowment fund in accordance with Section
      240.13d-1(b)(1)(ii)(F)&#894;</div>
    <div>(g) <font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</font> Parent holding company or control person in accordance with Section
      240.13d-1(b)(1)(ii)(G)&#894;</div>
    <div>(h) <font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</font> Savings association as defined in Section 3(b) of the Federal Deposit
      Insurance Act (12 U.S.C. 1813)&#894;</div>
    <div>(i) <font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</font> Church plan that is excluded from the definition of an investment
      company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3)&#894;</div>
    <div>(j) <font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9745;</font> A non-U.S. institution in accordance with Section
      240.13d-1(b)(1)(ii)(J)&#894;</div>
    <div>(k) <font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</font> Group, in accordance with Section 240.13d-1(b)(1)(ii)(K). If filing
      as a non-U.S. institution in accordance with Section 240.13d-1(b)(1)(ii)(J), please specify the type of</div>
    <div>institution: ____________________________ .</div>
    <div><br>
    </div>
    <div>Item 4 - Ownership:</div>
    <div>Amundi is a majority-owned affiliate of Credit Agricole S.A., a French bank. Amundi Asset Management is a wholly-owned subsidiary of Amundi.</div>
    <div><br>
    </div>
    <div>(a) Amount beneficially owned: See Item 9 of each cover page.</div>
    <div>(b) Percent of class: See Item 11 of each cover page.</div>
    <div>(c) Number of shares as to which the person has:</div>
    <div style="text-indent: 36pt;">(i) Sole power to vote or to direct the vote: See Item 5 of each cover page.</div>
    <div style="text-indent: 36pt;">(ii) Shared power to vote or to direct the vote: See Item 6 of each cover page.</div>
    <div style="text-indent: 36pt;">(iii) Sole power to dispose or to direct the disposition of: See Item 7 of each cover page.</div>
    <div style="text-indent: 36pt;">(iv) Shared power to dispose or to direct the disposition of: See Item 8 of each cover page.</div>
    <div>&#8195;</div>
    <div>Item 5 - Ownership of Five Percent or Less of a Class:</div>
    <div><br>
    </div>
    <div>If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5
      percent of the class of securities, check the following <font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</font></div>
    <div><br>
    </div>
    <div>Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:</div>
    <div><br>
    </div>
    <div>Not Applicable</div>
    <div><br>
    </div>
    <div>Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:</div>
    <div><br>
    </div>
    <div>See Attached Appendix A</div>
    <div><br>
    </div>
    <div>Item 8 - Identification and Classification of Members of Group:</div>
    <div><br>
    </div>
    <div>Not Applicable</div>
    <div><br>
    </div>
    <div>Item 9 - Notice of Dissolution of Group:</div>
    <div><br>
    </div>
    <div>Not Applicable</div>
    <div><br>
    </div>
    <div>Item 10 - Certification:</div>
    <div><br>
    </div>
    <div>By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of
      business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any
      transaction having that purpose or effect.</div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div>SIGNATURE</div>
    <div><br>
    </div>
    <div>After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.</div>
    <div><br>
    </div>
    <div>Dated: Executed as a sealed instrument this 7th day of November, 2024.</div>
    <div><br>
    </div>
    <div>Company Name</div>
    <div>Amundi</div>
    <div>By: /s/ Lisa M. Jones</div>
    <div>Name: Lisa M. Jones</div>
    <div>Title: President and Chief Executive Officer</div>
    <div>Head of the Americas</div>
    <div>Amundi US, Inc.</div>
    <div>By Power of Attorney</div>
    <div><br>
    </div>
    <div>Company Name</div>
    <div>Amundi Asset Management</div>
    <div>By: /s/ Lisa M. Jones</div>
    <div>Name: Lisa M. Jones</div>
    <div>Title: President and Chief Executive Officer</div>
    <div>Head of the Americas</div>
    <div>Amundi US, Inc.</div>
    <div>By Power of Attorney</div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div>AGREEMENT</div>
    <div><br>
    </div>
    <div>Each of the undersigned, pursuant to Rule 13d-1(k)(l) under the Securities Exchange Act of 1934, as amended, hereby agrees that only one statement containing
      the information required by Schedule 13G needs be filed with respect to the ownership by each of the undersigned of the shares of common stock of Sanofi that the Schedule 13G to which this Agreement is appended as Exhibit 1 is to be filed with the
      Securities and Exchange Commission on behalf of each of the undersigned on or about the date hereof.</div>
    <div><br>
    </div>
    <div>EXECUTED as a sealed instrument this 7th day of November, 2024.</div>
    <div><br>
    </div>
    <div>Company Name</div>
    <div>Amundi</div>
    <div>By: /s/ Lisa M. Jones</div>
    <div>Name: Lisa M. Jones</div>
    <div>Title: President and Chief Executive Officer</div>
    <div>Head of the Americas</div>
    <div>Amundi US, Inc.</div>
    <div>By Power of Attorney</div>
    <div><br>
    </div>
    <div>Company Name</div>
    <div>Amundi Asset Management</div>
    <div>By: /s/ Lisa M. Jones</div>
    <div>Name: Lisa M. Jones</div>
    <div>Title: President and Chief Executive Officer</div>
    <div>Head of the Americas</div>
    <div>Amundi US, Inc.</div>
    <div>By Power of Attorney</div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div>Appendix A</div>
    <div><br>
    </div>
    <div>Subsidiary:</div>
    <div><br>
    </div>
    <div>AMUNDI AM</div>
    <div>AMUNDI AUSTRIA GMBH</div>
    <div>AMUNDI CZECH REPUBLIC</div>
    <div>AMUNDI DEUTSCHLAND GMBH</div>
    <div>AMUNDI HONG KONG</div>
    <div>AMUNDI IRELAND LIMITED</div>
    <div>AMUNDI JAPAN</div>
    <div>AMUNDI ASSET MANAGEMENT US, INC.</div>
    <div>AMUNDI SGR</div>
    <div>AMUNDI SINGAPORE</div>
    <div>BFT INVESTMENT MANAGERS</div>
    <div>CPR</div>
    <div>KBI Global Investors (North America) Ltd</div>
    <div>KBI Global Investors Ltd</div>
    <div>S2G</div>
    <div>SABADELL ASSET MANAGEMENT</div>
    <div>Morgan Stanley Smith Barney LLC</div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
